In conclusion, Pul-PGEA-pCas-sgVs-1 nanoparticles can inhibit the development of abdominal aortic aneurysm by decreasing the expression levels of hs-CRP, ICAM-1, VCAM-1, and TNF-a, which provides a new idea for gene therapy of abdominal aortic aneurysm. This evidence concerns the gene TNF and abdominal aortic aneurysm.